Key Points
- Agios insider Sarah Gheuens sold 1,489 shares for approximately $55,882 at an average price of $37.53 under a pre-arranged Rule 10b5-1 plan, reducing her holdings by 2.65% to 54,645 shares.
- AGIO opened at $37.00, with a market capitalization of approximately $2.21 billion; the stock has traded between $22.24 and $46.00 over the past year.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $41.50, while Agios recently reported a quarterly EPS loss of $1.69 and revenue of $44.75 million.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 500 shares of the company's stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $37.52, for a total value of $18,760.00. Following the sale, the insider owned 54,645 shares of the company's stock, valued at $2,050,280.40. This represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sarah Gheuens also recently made the following trade(s):
- On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.53, for a total value of $55,882.17.
- On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $30.48, for a total value of $914,400.00.
Agios Pharmaceuticals Stock Down 0.5%
Shares of NASDAQ AGIO traded down $0.19 during midday trading on Friday, hitting $37.00. The stock had a trading volume of 920,048 shares, compared to its average volume of 1,213,961. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -5.28 and a beta of 0.63. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00. The company has a fifty day moving average price of $33.41 and a 200 day moving average price of $32.79.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.04). The firm had revenue of $44.75 million for the quarter, compared to analysts' expectations of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. On average, research analysts forecast that Agios Pharmaceuticals, Inc. will post -5.83 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth $239,582,000. Assenagon Asset Management S.A. boosted its position in Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company's stock valued at $62,723,000 after buying an additional 1,782,457 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter valued at about $47,800,000. Dimensional Fund Advisors LP boosted its position in Agios Pharmaceuticals by 14.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company's stock valued at $38,940,000 after buying an additional 147,273 shares during the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new stake in shares of Agios Pharmaceuticals during the second quarter valued at about $24,828,000.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on AGIO. TD Cowen raised shares of Agios Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 24th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. Bank of America increased their price target on Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a "buy" rating in a report on Monday, September 21st. Citigroup raised their price objective on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. boosted their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $41.50.
Get Our Latest Report on AGIO
Agios Pharmaceuticals Company Profile
(
Get Free Report)
Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company's research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.
Agios' principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
